H. David Humes, M.D., graduated from the medical school of the University of California, San Francisco, and joined the faculties of Harvard Medical School and the University of Michigan and is a board certified Nephrologist on staff at the University of Michigan. He has chaired the University of Michigan’s Department of Internal Medicine and presently holds the rank of Professor. He has published over 200 scientific articles and book chapters and was editor-in-chief of Kelley’s Textbook of Internal Medicine. Additionally, he has 70 patents issued or pending. He is an international authority in the areas of acute renal failure, stem cell biology, and tissue engineering. His laboratory has received international attention for its work in the development of the bioartificial kidney. Dr. Humes has been elected to a number of prestigious honorary scientific societies, and a number of highly acclaimed awards in Nephrology have been bestowed on him, including The President’s Award from the National Kidney Foundation and the A.N. Richards Distinguished Achievement Award in Nephrology. Dr. Humes is active in the for-profit sector. Most notably, he is the scientific founder of CytoPherx (formerly Nephrion and RenaMed Biologics, Inc.), a biotechnology company directed toward various devices to treat acute organ failure; and Innovative BioTherapies, Inc., a company developing nanofabricated replacement organs utilizing stem cells. He is also on the Medical Advisory Boards of Renal Solutions, Inc., and Natural Therapeutics, Inc. He is the Chairman of the Michigan Center for Regenerative Medicine.

 Nephrology